Patents by Inventor Neil E. Simister
Neil E. Simister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7547436Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: February 23, 2006Date of Patent: June 16, 2009Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Wayne I. Lencer, Neil E. Simister
-
Patent number: 7067129Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: August 8, 2002Date of Patent: June 27, 2006Assignees: The Brigham and Woman's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Patent number: 7060274Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: August 8, 2002Date of Patent: June 13, 2006Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Publication number: 20040063912Abstract: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long.Type: ApplicationFiled: July 17, 2003Publication date: April 1, 2004Applicants: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, Brandeis University, Syntonix Pharmaceuticals, Inc.Inventors: Richard S. Blumberg, Wayne I. Lencer, Neil E. Simister, Alan J. Bitonti
-
Publication number: 20030235536Abstract: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.Type: ApplicationFiled: May 9, 2003Publication date: December 25, 2003Applicants: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, Brandeis University, Syntonix Pharmaceuticals, Inc.Inventors: Richard S. Blumberg, Wayne I. Lencer, Neil E. Simister, Alan J. Bitonti
-
Publication number: 20030012789Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: ApplicationFiled: August 8, 2002Publication date: January 16, 2003Inventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Publication number: 20020192222Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: ApplicationFiled: August 8, 2002Publication date: December 19, 2002Inventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Patent number: 6485726Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: July 24, 1998Date of Patent: November 26, 2002Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer
-
Patent number: 6086875Abstract: Methods and products for modulating an immune response are provided. Pharmaceutical preparations contain a conjugate of an antigen and a FcRn binding partner. The conjugates are administered to mammals in effective amounts to modulate the immune system by stimulating the immune response against the antigen or tolerizing the immune system to the antigen. The antigen may be characteristic of a pathogen, of an autoimmune disease or of an allergen.Type: GrantFiled: January 17, 1995Date of Patent: July 11, 2000Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne L. Lencer
-
Patent number: 6030613Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: GrantFiled: July 24, 1997Date of Patent: February 29, 2000Assignees: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard S. Blumberg, Neil E. Simister, Wayne I. Lencer